DCA are pleased to announce that Sanofi’s new Lyxumia® pen-injector for diabetes patients in Japan has won a prestigious Good Design Award; issued by the Japan Institute for Design Promotion.
The new Lyxumia® pen is the result of a rigorous device development programme undertaken by Sanofi and DCA and builds on the hugely successful, multi-award winning SoloStar® device platform.
Established in 1957 in Japan, the Good Design Award is a comprehensive program for the evaluation and encouragement of design. Detailed screening is carried out to select the Good Design Award winners, which covers topics such as aesthetic quality, consideration for the environment, usability and the contribution made to society.
DCA’s Managing Director, Rob Woolston commented “The new Lyxumia® pen represents another good example of our approach to design. This is a device that has been developed with very careful consideration of the intended market and for the needs of users within that market. We are delighted that this product has been recognised with this prestigious award.”
(Lyxumia® is a registered brand of Sanofi Aventis).
